Modern Pediatrics. Ukraine. (2022). 7(127): 38-45. doi 10.15574/SP.2022.127.38
Dobryk D. S.,Dobryanskyy D. O.
Danylo Halytsky Lviv National Medical University, Ukraine

For citation: Dobryk DS, Dobryanskyy DO. (2022). Fecal calprotectin, lactoferrin and morbidity associated with immature digestive tract in preterm infants. Modern Pediatrics. Ukraine. 7(127): 38–45. doi 10.15574/SP.2022.127.38.
Article received: Sep 17, 2022. Accepted for publication: Nov 15, 2022.

Introduction. Excessive intestinal inflammation in preterm infants is one of the key factors in the development of necrotizing enterocolitis (NEC), early- (EOS) and late-onset neonatal sepsis (LOS).
Purpose – to evaluate the connection between fecal calprotectin (FC), enteral use of lactoferrin (LF), and the occurrence of NEC, EOS, and LOS in preterm infants.
Materials and methods. FC was measured in 26 newborns with gestational age (GA) ≤32 weeks and birth weight ≤1500 g. Feces were collected twice: in the first 7 days of life and at the postmenstrual age (PMA) of 36 weeks. The main group included 15 infants with either EOS, LOS or NEC. The remaining 11 infants formed the comparison group. Eleven infants received LF (4 in the main group and 7 in the comparison group), which was randomly administered in the first 3 days of life.
Results. FC in the first 7 days of life was higher in the main group (р>0.05). At the PMA of 36 weeks, FC decreased in the main group and increased in the comparison group (p>0.05). FC in the first week of life was higher in infants with EOS compared to newborns without the diseases (p=0.03), followed by a decrease at the PMA of 36 weeks (p=0.04). There was no significant difference in FC levels depending on the development of LOS or NEC. FC levels increased in all infants who received LF and decreased in babies who did not receive LF (p>0.05).
Conclusions. The occurrence of EOS is associated with a significant increase in FC which subsequently decrease by the PMA of 36 weeks. FC in the first week of life are not associated with the development of NEC or LOS. Enteral use of LF at a dose of 100 mg/day is associated with an increase in FC levels (p>0.05).
The research was carried out in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Local Ethics Committee of the participating institution. The informed consent of the patient was obtained for conducting the studies.
No conflict of interests was declared by the authors.
Keywords: fecal calprotectin, lactoferrin, neonatal sepsis, necrotizing enterocolitis, preterm infants.
REFERENCES
1. Aadland E, Fagerhol MK. (2002). Faecal calprotectin: a marker of inflammation throughout the intestinal tract. European Journal of Gastroenterology & Hepatology. 14 (8): 823-825. https://doi.org/10.1097/00042737-200208000-00002; PMid:12172400

2. Asgarshirazi M, Shariat M, Nayeri F, Dalili H, Abdollahi A. (2017). Comparison of Fecal Calprotectin in Exclusively Breastfed and Formula or Mixed Fed Infants in the First Six Months of Life. Acta Med Iran. 55: 1. https://doi.org/10.5812/compreped.59992

3. Aydemir O, Aydemir C, Sarikabadayi YU, Emre Canpolat F, Erdeve O, Biyikli Z, Dilmen U. (2012). Fecal calprotectin levels are increased in infants with necrotizing enterocolitis. The Journal of Maternal-Fetal & Neonatal Medicine. 25 (11): 2237-2241. https://doi.org/10.3109/14767058.2012.684172; PMid:22524488

4. Decembrino L, De Amici M, Pozzi M, De Silvestri A, Stronati M. (2015). Serum Calprotectin: A Potential Biomarker for Neonatal Sepsis. Journal of Immunology Research. 2015: 1-4. https://doi.org/10.1155/2015/147973; PMid:26380313 PMCid:PMC4563108

5. Dobryk D, Dobryk O, Dobryanskyy D. (2022). The effect of enteral lactoferrin supplementation in prevention of morbidity associated with immature digestive tract in premature infants: prospective cohort study. Georgian Medical News. 323: 94-101. URL: http://www.ncbi.nlm.nih.gov/pubmed/35271478.

6. Ewaschuk JB, Unger S, O'Connor DL, Stone D, Harvey S, Clandinin MT, Field CJ. (2011). Effect of pasteurization on selected immune components of donated human breast milk. Journal of Perinatology. 31 (9): 593-598. https://doi.org/10.1038/jp.2010.209; PMid:21330996

7. Groer M, Ashmeade T, Louis-Jacques A, Beckstead J, Ji M. (2016). Relationships of Feeding and Mother's Own Milk with Fecal Calprotectin Levels in Preterm Infants. Breastfeeding Medicine. 11 (4): 207-212. https://doi.org/10.1089/bfm.2015.0115; PMid:27002351 PMCid:PMC4860673

8. Johne B, Fagerhol MK, Lyberg T, Prydz H, Brandtzaeg P, Naess-Andresen CF, Dale I. (1997). Functional and clinical aspects of the myelomonocyte protein calprotectin. Molecular Pathology. 50 (3): 113-123. https://doi.org/10.1136/mp.50.3.113; PMid:9292145 PMCid:PMC379605

9. Josefsson S, Bunn SK, Domellöf M. (2007). Fecal Calprotectin in Very Low Birth Weight Infants. Journal of Pediatric Gastroenterology & Nutrition. 44 (4): 407-413. https://doi.org/10.1097/MPG.0b013e3180320643; PMid:17414135

10. Kliegman RM, Walsh MC. (1987). Neonatal necrotizing enterocolitis: Pathogenesis, classification, and spectrum of illness. Current Problems in Pediatrics. 17 (4): 219-288. https://doi.org/10.1016/0045-9380(87)90031-4; PMid:3556038

11. Legrand D. (2012). Lactoferrin, a key molecule in immune and inflammatory processes. Biochemistry and Cell Biology. 90 (3): 252-268. https://doi.org/10.1139/o11-056; PMid:22136726

12. Legrand D. (2016). Overview of Lactoferrin as a Natural Immune Modulator. The Journal of Pediatrics. 173: S10-S15. https://doi.org/10.1016/j.jpeds.2016.02.071; PMid:27234406

13. Liao Y, Jiang R, Lönnerdal B. (2012). Biochemical and molecular impacts of lactoferrin on small intestinal growth and development during early life. Biochemistry and Cell Biology. 90 (3): 476-484. https://doi.org/10.1139/o11-075; PMid:22332905

14. MacQueen BC, Christensen RD, Yost CC, Gordon PV, Baer VL, Schlaberg R, Lowe J. (2018). Reference intervals for stool calprotectin in preterm neonates and their utility for the diagnosis of necrotizing enterocolitis. Journal of Perinatology. 38 (10): 1379-1385. https://doi.org/10.1038/s41372-018-0108-9; PMid:29740189

15. Mara MA, Good M, Weitkamp J-H. (2018). Innate and adaptive immunity in necrotizing enterocolitis. Seminars in Fetal and Neonatal Medicine. 23 (6): 394-399. https://doi.org/10.1016/j.siny.2018.08.002; PMid:30146477 PMCid:PMC6269198

16. Milton R, Gillespie D, Dyer C, Taiyari K, Carvalho MJ, Thomson K et al. (2022). Neonatal sepsis and mortality in low-income and middle-income countries from a facility-based birth cohort: an international multisite prospective observational study. The Lancet Global Health. 10 (5): e661-e672. https://doi.org/10.1016/S2214-109X(22)00043-2; PMid:35427523

17. Niño DF, Sodhi CP, Hackam DJ. (2016). Necrotizing enterocolitis: new insights into pathogenesis and mechanisms. Nature Reviews Gastroenterology & Hepatology. 13 (10): 590-600. https://doi.org/10.1038/nrgastro.2016.119; PMid:27534694 PMCid:PMC5124124

18. Pirr S, Dauter L, Vogl T, Ulas T, Bohnhorst B, Roth J, Viemann D. (2021). S100A8/A9 is the first predictive marker for neonatal sepsis. Clinical and Translational Medicine. 11(4): https://doi.org/10.1002/ctm2.338; PMid:33931974 PMCid:PMC8021540

19. Rougé C, Butel M-J, Piloquet H, Ferraris L, Legrand A, Vodovar M et al. (2010). Fecal Calprotectin Excretion in Preterm Infants during the Neonatal Period. PLoS ONE. 5 (6): e11083. https://doi.org/10.1371/journal.pone.0011083; PMid:20552029 PMCid:PMC2884033

20. Savino F, Castagno E, Calabrese R, Viola S, Oggero R, Miniero R. (2010). High Faecal Calprotectin Levels in Healthy. Exclusively Breast-Fed Infants: 299-304. https://doi.org/10.1159/000255161; PMid:19887860

21. Terrin G, Passariello A, Manguso F, Salvia G, Rapacciuolo L, Messina F, Raimondi F, Canani RB. (2011). Serum Calprotectin: An Antimicrobial Peptide as a New Marker For the Diagnosis of Sepsis in Very Low Birth Weight Newborns. Clinical and Developmental Immunology. 2011: 1-6. https://doi.org/10.1155/2011/291085; PMid:21765851 PMCid:PMC3135082

22. Thibault M-P, Tremblay É, Horth C, Fournier-Morin A, Grynspan D, Babakissa C et al. (2022). Lipocalin-2 and calprotectin as stool biomarkers for predicting necrotizing enterocolitis in premature neonates. Pediatric Research. 91 (1): 129-136. https://doi.org/10.1038/s41390-021-01680-7; PMid:34465872 PMCid:PMC8770124

23. Tirone C, Pezza L, Paladini A, Tana M, Aurilia C, Lio A et al. (2019). Gut and Lung Microbiota in Preterm Infants: Immunological Modulation and Implication in Neonatal Outcomes. Frontiers in Immunology: 10. https://doi.org/10.3389/fimmu.2019.02910; PMid:31921169 PMCid:PMC6920179

24. Ullah O, Khan A, Ambreen A, Ahmad I, Akhtar T, Gandapor AJ, Khan AM. (2016). Antibiotic Sensitivity pattern of Bacterial Isolates of Neonatal Septicemia in Peshawar, Pakistan. Archives of Iranian Medicine. 19 (12): 866-869. https://doi.org/0161912/AIM.009.

25. Van Zoonen AGJF, Hulzebos CV, Muller Kobold AC, Kooi EMW, Bos AF, Hulscher JBF. (2019). Serial fecal calprotectin in the prediction of necrotizing enterocolitis in preterm neonates. Journal of Pediatric Surgery. 54 (3): 455-459. https://doi.org/10.1016/j.jpedsurg.2018.04.034; PMid:29859621

26. Wang B, Timilsena YP, Blanch E, Adhikari B. (2019). Lactoferrin: Structure, function, denaturation and digestion. Critical Reviews in Food Science and Nutrition. 59 (4): 580-596. https://doi.org/10.1080/10408398.2017.1381583; PMid:28933602

27. Yoon JM, Park JY, Ko KO, Lim JW, Cheon EJ, Kim HJ. (2014). Fecal calprotectin concentration in neonatal necrotizing enterocolitis. Korean Journal of Pediatrics. 57 (8): 351-356. https://doi.org/10.3345/kjp.2014.57.8.351; PMid:25210522 PMCid:PMC4155179

28. Yui S, Nakatani Y, Mikami M. (2003). Calprotectin (S100A8/S100A9), an Inflammatory Protein Complex from Neutrophils with a Broad Apoptosis-Inducing Activity. Biological and Pharmaceutical Bulletin. 26 (6): 753-760. https://doi.org/10.1248/bpb.26.753; PMid:12808281

29. Zhang M, Zhang X, Zhang J. (2016). Diagnostic Value of Fecal Calprotectin in Preterm Infants with Necrotizing Enterocolitis. Clinical Laboratory, 62(05/2016). https://doi.org/10.7754/Clin.Lab.2015.150906